More Neurizon Therapeutics Limited news
Neurizon Therapeutics LimitedASX: NUZ

PharmAust Commences GMP Tablet Manufacture for Phase 2 Trial

Jun 3, 2019 at 10:51 PM EDT · Issued by Neurizon Therapeutics Limited

Filed with ASX · Jun 3, 2019 at 10:51 PM EDT · 2 pages · English

On 6ix: 6ix.com/news/pharmaust-commences-gmp-tablet-manufacture-for-phase-2-trial

Neurizon Therapeutics Limited on 6ix

Story so far

  • Phase I Dog Trial with New Monepantel Tablets CommencesFeb 20, 2019
  • GMP Tablet Manufacture Commences for Canine Clinical TrialsNov 13, 2018
  • Phase II Dog Lymphoma Trial Confirms MPL Clinical BenefitDec 13, 2017

Earlier from Neurizon Therapeutics

  • Receipt of 25kg of GMP-Grade Monepantel from ElancoMay 8, 2019
  • Phase I Canine Repeat Dose MPL Demonstrates High PerformanceMay 5, 2019
  • PharmAust Receives $672,250 R&D Tax Incentive RefundApr 29, 2019
  • Shortfall Placement OversubscribedApr 11, 2019
  • Phase I Monepantel Tablets Demonstrate High SafetyMar 27, 2019

Later from Neurizon Therapeutics

  • Epichem Final Loan Repayment Milestone for New LaboratoryJul 1, 2019
  • PharmAust receives ethics approval to begin Phase II TrialJul 14, 2019
  • Response to ASX Price and Volume QueryJul 23, 2019
  • Receipt of GMP Grade Tablets for Phase II TrialsAug 25, 2019
  • Preliminary Final ReportAug 30, 2019
All Neurizon Therapeutics news releases↗

Follow Neurizon Therapeutics into a list and get an email when it puts out news.

Follow Neurizon Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer